A novel helmet that generates a noninvasive oscillating magnetic field was able to reduce tumor mass by 31% in a glioblastoma brain cancer patient.
Engineering NK cells to resist immune suppression could be a path toward using NK cell-based immunotherapies for glioblastoma brain cancer.
Combining αGITR antibodies with ICBs resulted in stronger survival benefits in mouse models of human glioblastoma brain cancer.
Glioblastoma can mimic the normal repair of white matter in the brain, causing the tumor to become less malignant. Additionally, a drug commonly prescribed for asthma can help suppress glioblastoma growth in mouse models.
A newly developed ion pump can deliver cancer-fighting drugs more accurately, and with fewer side effects than conventional chemotherapy, to those with glioblastoma brain cancer.
Administering the chemotherapy drug temozolomide to glioblastoma brain cancer patients in the morning may enhance the cancer-fighting effects. The study demonstrates the timing of chemotherapy could have a significant impact on treatment for glioblastoma patients.
Study shows how cholesterol becomes dysregulated in brain cancer cells and reports the gene responsible for the dysregulation could be a potential target to help treat glioblastoma brain cancer.
Researchers have developed a Dp44mT nano-carrier that can directly target glioblastoma and other brain cancer cells.
Disabling the CD161 pathway restores the T-cell's ability to attack gliomas and extends lifespan in animal models of brain cancer.
A new zebrafish model holds the potential for future studies of glioblastoma, an aggressive and lethal brain cancer.
Study reveals a detailed map of gene proteins, infiltrating cells, and signaling pathways that play significant roles in the development and progression of glioblastoma brain cancer.
Inhibiting the SCD enzyme and blocking the function of FOSB blunts acquired drug resistance and improves survival in mouse models of glioblastoma brain cancer.
